Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
This modest shift reflects growing confidence in the company's streamlined respiratory focus, clearer execution path, and more disciplined capital allocation after the Trelegy monetization, even as assumptions for future revenue growth become more conservative at roughly 23.28%. Stay tuned to see how investors can track these evolving assumptions and keep up with the changing story behind Theravance Biopharma's valuation. Stay updated as the Fair Value for Theravance Biopharma shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Theravance Biopharma. ?? Bullish Takeaways There is currently limited formal Street coverage available, and recent published notes have not provided detailed ratings, targets, or written rationale that can be summarized here. As a result, there is not enough disclosed information to extract specific bullish points on Theravance Biopharma's valuation, execution, or growth prospects from
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TBPH&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Theravance Biopharma (NASDAQ:TBPH) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TBPH&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.MarketBeat
- Theravance Biopharma (NASDAQ:TBPH) had its price target raised by analysts at BTIG Research from $25.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
TBPH
Earnings
- 11/10/25 - Beat
TBPH
Sec Filings
- 12/8/25 - Form 8-K
- 12/5/25 - Form 4
- 12/3/25 - Form 144
- TBPH's page on the SEC website